E2 therapy induced cell cycle progression and promoted cell survival by ERα-mediated mechanisms, whereas its treatment also triggered apoptosis by activating Casp-3 via ERβ in DLD1 CRC cells (50). Here, CASP3 is linked to colorectal carcinoma.